🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

Recruitingn/aAges 12 Years - anyAllPeking University Third Hospital
NCT07153666 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age12 years or older, any gender; 2. Signed"Informed Consent Form"; 3. Clinically diagnosed with non-segmental vitiligo; 4. Vitiligo area less than 10% of body surface area; 5. Agreed to discontinue all other vitiligo-related treatments from the screening visit until the final follow-up visit; 6. Female subjects must not plan for pregnancy or oocyte donation from screening until 4 weeks after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include: * Barrier methods: Condom or barrier cap (diaphragm or cervical cap); * Intrauterine device (IUD) or intrauterine system (IUS); * Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner; * Other investigator-confirmed highly effective physical contraception. Exclusion Criteria: 1. Allergy to ruxolitinib cream; 2. Pregnant or lactating women; 3. Any condition deemed inappropriate for study participation by the investigator.
💊

What it tests

  • Ruxolitinib 1.5% Cream BID
📍

Where

1 site
Peking University Third Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy